| Literature DB >> 35022421 |
Ginga Suzuki1, Ryo Ichibayashi2, Yuka Masuyama2, Saki Yamamoto2, Hibiki Serizawa2, Yoshimi Nakamichi2, Masayuki Watanabe2, Mitsuru Honda2.
Abstract
The objective of this single-center retrospective cohort study was to investigate the relationship between blood transfusion and persistent inflammation, immunosuppression, and catabolism syndrome (PIICS). The study was conducted at the Critical Care Center at Toho University Omori Medical Center, Japan. We included 391 patients in the PIICS group (hospitalization for > 15 days, C-reactive protein > 3.0 mg/dL or albumin < 3.0 mg/dL or lymph < 800/μL on day 14) and 762 patients in the non-PIICS group (hospitalization for > 15 days and not meeting the PIICS criteria). We performed univariate and multivariate logistic regression analyses using PIICS as the objective variable and red blood cell (RBC) or fresh frozen plasma or platelet (PLT) transfusion and other confounding factors as explanatory variables. In addition, we conducted a sensitivity analysis using propensity score matching analysis. The multivariate and propensity score analyses showed that RBC and PLT transfusions were significantly associated with PIICS. This is the first study to report an association between RBC and PLT transfusions and PIICS. Our findings have contributed to better understanding the risk factors of PIICS and suggest that physicians should consider the risk of PIICS occurrence when administering blood transfusions in intensive care unit (ICU) patients.Entities:
Mesh:
Year: 2022 PMID: 35022421 PMCID: PMC8755792 DOI: 10.1038/s41598-021-04327-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Chart showing the patient selection process. PIICS persistent inflammation, immunosuppression, and catabolism syndrome.
Basic characteristics of overall and matched cohort.
| Variable | Overall cohort | Matched cohort | ||||
|---|---|---|---|---|---|---|
| Non-PIICS group (n = 762) | PIICS group (n = 391) | p | Non-PIICS group (n = 144) | PIICS group (n = 162) | p | |
| Age, years | 62.0 (30.0) | 72.0 (22.0) | < 0.01 | 72.0 (23.6) | 73.0 (20.0) | 0.11 |
| Male, n (%) | 494 (65.2%) | 260 (66.5%) | 0.65 | 94 (65.3%) | 97 (59.9%) | 0.33 |
| < 0.01 | 0.01 | |||||
| Cardiovascular, n (%) | 115.0 (15.2) | 64.0 (16.4) | 24.0 (16.7) | 20.0 (12.3) | ||
| Respiratory, n (%) | 56.0 (7.4) | 26.0 (6.6) | 11.0 (7.6) | 7.0 (4.3) | ||
| Digestive, n (%) | 60.0 (7.9) | 37.0 (9.5) | 22.0 (15.3) | 9.0 (5.6) | ||
| Neurological, n (%) | 76.0 (10.0) | 80.0 (20.5) | 13.0 (9.0) | 39.0 (24.1) | ||
| Metabolic, n (%) | 22.0 (2.9) | 11.0 (2.8) | 3.0 (2.1) | 5.0 (3.1) | ||
| Sepsis, n (%) | 24.0 (3.1%) | 57.0 (14.6%) | 10.0 (6.9%) | 31.0 (19.1%) | ||
| Abnormal body temperature, n (%) | 33.0 (4.4) | 14.0 (3.6) | 10.0 (6.9) | 6.0 (3.7) | ||
| Cardiac arrest, n (%) | 21.0 (2.8) | 38.0 (9.7) | 6.0 (4.2) | 14.0 (8.6) | ||
| Trauma, n (%) | 154.0 (20.3) | 37.0 (9.5) | 25.0 (17.4) | 17.0 (10.5) | ||
| Others, n (%) | 198.0 (26.1) | 27.0 (7.4) | 20.0 (13.9) | 9.0 (5.6) | ||
| Surgical procedure, n (%) | 45.0 (5.9%) | 110.0 (28.1%) | < 0.01 | 29 (20.1%) | 54 (33.3%) | 0.01 |
| Charlson comorbidity index | 0 (2.0) | 1.0 (2.0) | < 0.01 | 1.0 (1.0) | 1.0 (1.0) | 0.55 |
| Chronic heart failure, n (%) | 46.0 (6.1) | 29 (7.4) | 0.38 | 11.0 (7.6) | 14.0 (8.6) | |
| Stroke, n (%) | 68.0 (9.0) | 44.0 (11.3) | 0.22 | 5.0 (3.5) | 3.0 (1.9) | |
| COPD, n (%) | 35.0 (4.6) | 12.0 (3.1) | 0.21 | 7.0 (4.9) | 8.0 (4.9) | |
| Diabetes mellitus, n (%) | 121.0 (16.0) | 76.0 (19.4) | 0.14 | 22.0 (15.3) | 31.0 (19.1) | |
| Cancer, n (%) | 78.0 (10.3) | 51.0 (13.0) | 0.16 | 23.0 (16.0) | 21.0 (13.0) | |
| C-reactive protein, mg/dL | 0.1 (0.6) | 0.8 (5.8) | < 0.01 | 0.2 (1.4) | 0.9 (6.0) | < 0.01 |
| Albumin, mg/dL | 3.9 (0.9) | 3.3 (1.1) | < 0.01 | 3.6 (0.9) | 3.3 (1.3) | 0.03 |
| Creatinine, mg/mL | 0.9 (0.5) | 1.1 (1.0) | < 0.01 | 1.0 (0.9) | 1.2 (1.0) | 0.20 |
| Lymphocyte counts, /μL | 1849.0 (1876.8) | 1185.0 (1986.9) | < 0.01 | 1439.5 (1945.2) | 1139.5 (2136.9) | 0.40 |
| Hemoglobin, g/dL | 13.4 (3.1) | 12.7 (4.1) | < 0.01 | 11.3 (4.0) | 12.3 (4.0) | 0.02 |
| Lactate, mmol/L | 2.7 (3.2) | 3.4 (5.3) | < 0.01 | 2.7 (3.5) | 3.1 (5.1) | 0.20 |
| HbA1c, % | 5.6 (0.7) | 5.7 (1.0) | 0.01 | 5.6 (0.7) | 5.7 (1.0) | < 0.01 |
| APACHE II score | 14.0 (12.0) | 20.0 (12.0) | < 0.01 | 17.0 (11.0) | 20.0 (11.0) | 0.01 |
| Overt DIC, (%) | 9.0 (1.2%) | 21.05.4%) | < 0.01 | 6.0 (4.2%) | 9.0 (5.6%) | 0.57 |
COPD chronic obstructive pulmonary disease, APACHE acute physiologic and chronic health evaluation, DIC disseminated intravascular coagulation, PIICS persistent inflammation, immunosuppression, and catabolism syndrome.
Variables on day 14 and outcomes.
| Variable | Non-PIICS group (n = 762) | PIICS group (n = 391) | p |
|---|---|---|---|
| C-reactive protein, mg/dL | 0.5 (1.5) | 3.6 (5.8) | < 0.01 |
| Albumin, mg/dL | 3.5 (0.7) | 2.4 (0.7) | < 0.01 |
| Lymphocyte counts, /μL | 1432.9 (869.5) | 1008.0 (688.2) | < 0.01 |
| Red blood cell, n (%) | 83.0 (10.9%) | 193.0 (49.4%) | < 0.01 |
| Storage time, day | 12.0 (1.5) | 12.0 (1.5) | 0.38 |
| Plasma, ml, n (%) | 38.0 (5.0%) | 110.0 (28.1%) | < 0.01 |
| Storage time, day | 269.5 (14.0) | 266.0 (15.0) | 0.67 |
| Platelet, n (%) | 6.0 (0.8%) | 69.0 (17.6%) | < 0.01 |
| Storage time, day | 2.5 (0.5) | 3.0 (0.5) | 0.49 |
| Steroids use on day 14, n (%) | 36.0 (4.8%) | 54.0 (13.9%) | < 0.01 |
| Immunosuppressant use, n (%) | 1.0 (0.1%) | 5.0 (1.3%) | 0.02 |
| Vasopressor use on day 14, n (%) | 100.0 (13.2) | 208.0 (53.2) | < 0.01 |
| Shock on day 14, n (%) | 79.0 (10.4) | 154.0 (39.4) | < 0.01 |
| Duration of MV on day 14, day | 0 (0) | 1.0 (5.5) | < 0.01 |
| RRT on day 14, n (%) | 33.0 (4.4) | 39.0 (10.0%) | < 0.01 |
| ECMO on day 14, n (%) | 3.0 (0.4%) | 24.0 (6.1%) | < 0.01 |
| 90-day mortality | 2.0 (0.3%) | 57.0 (14.6%) | < 0.01 |
PIICS persistent inflammation, immunosuppression, and catabolism syndrome, MV mechanical ventilation, RRT renal replacement therapy, ECMO extracorporeal membrane oxygenation.
Univariate and multivariate analysis of PIICS in the overall cohort.
| Parameters | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | VIF | |
| Age | 1.032 (1.025–1.040) | < 0.01 | 1.019 (1.005–1.032) | 0.01 | 2.08 |
| Male | 1.061 (0.820–1.372) | 0.65 | 0.952 (0.579–1.566) | 0.85 | 2.01 |
| Sepsis | 5.248 (3.202–8.601) | < 0.01 | 1.311 (1.008–1.707) | 0.04 | 1.08 |
| Surgical procedure | 6.202 (4.270–9.009) | < 0.01 | 5.089 (2.793–9.271) | < 0.01 | 1.55 |
| CCI | 1.120 (1.028–1.220) | 0.01 | 1.030 (0.906–1.171) | 0.65 | 1.36 |
| C-reactive protein | 1.086 (1.062–1.109) | < 0.01 | 1.028 (1.000–1.058) | 0.04 | 1.56 |
| Albumin | 0.367 (0.306–0.441) | < 0.01 | 0.471 (0.340–0.652) | < 0.01 | 2.39 |
| Creatinine | 1.108 (1.036–1.186) | < 0.01 | 0.984 (0.878–1.103) | 0.79 | 1.60 |
| Lymphocyte counts | 1.000 (1.000–1.000) | < 0.01 | 1.000 (1.000–1.000) | < 0.01 | 1.22 |
| HbA1c | 1.125 (1.028–1.230) | 0.01 | 1.027 (0.912–1.155) | 0.66 | 1.15 |
| Hemoglobin | 0.902 (0.862–0.943) | < 0.01 | 1.118 (1.025–1.219) | 0.01 | 2.27 |
| APACHE II score | 1.086 (1.069–1.104) | < 0.01 | 1.060 (1.030–1.091) | < 0.01 | 2.00 |
| Overt DIC | 4.749 (2.154–10.471) | < 0.01 | 2.218 (0.802–5.644) | 0.13 | 1.08 |
| Red blood cell | 7.974 (5.895–10.786) | < 0.01 | 3.094 (1.822–5.253) | < 0.01 | 2.35 |
| Plasma | 7.458 (5.031–11.057) | < 0.01 | 0.727 (0.352–1.503) | 0.39 | 2.40 |
| Platelets | 27.000 (11.606–62.815) | < 0.01 | 3.303 (1.134–9.625) | 0.03 | 1.91 |
| Duration of MV on day 14 | 1.347 (1.289–1.407) | < 0.01 | 1.280 (1.192–1.375) | < 0.01 | 2.93 |
CCI Charlson Comorbidity Index, APACHE acute physiologic and chronic health evaluation, DIC disseminated intravascular coagulation, HbA1c glycated hemoglobin, MV mechanical ventilation, PIICS persistent inflammation, immunosuppression, and catabolism syndrome, VIF variance inflation factor, CI confidence interval.
Figure 2Receiver operating characteristic curve showing the diagnostic value of the volume of red blood cell transfused in predicting PIICS in ICU patients. The area under the curve is 0.70. ROC receiver operating characteristic, PIICS persistent inflammation, immunosuppression, and catabolism syndrome.
Multivariate analysis of PIICS in the matched cohort.
| Parameters | Multivariate analysis | ||
|---|---|---|---|
| Odds ratio (95% CI) | p value | VIF | |
| C-reactive protein | 1.037 (1.004–1.080) | 0.03 | 1.54 |
| Albumin | 0.746 ( 0.490–1.134) | 0.17 | 1.39 |
| Creatinine | 0.994 (0.860–1.148) | 0.93 | 1.19 |
| Lymphocyte counts | 1.000 (1.000–1.000) | 0.43 | 1.08 |
| HbA1c | 1.392 (1.063–1.879) | 0.02 | 1.08 |
| Steroids | 0.535 (0.180–1.594) | 0.53 | 1.19 |
| Red blood cell | 3.186 (1.798–5.629) | < 0.01 | 2.84 |
| Plasma | 0.973 (0.906–1.045) | 0.97 | 2.681 |
| Platelets | 1.077 (1.022–1.135) | < 0.01 | 1.78 |
| Shock | 2.107 (0.972–4.566) | 0.06 | 1.70 |
| immunosuppressant | 1.882 (0.165–9.720) | 0.73 | 1.05 |
| Vasopressor | 0.685 (0.298–1.570) | 0.37 | 2.51 |
| Duration of ventilation | 1.263 (1.147–1.391) | < 0.01 | 2.24 |
MV mechanical ventilation, PIICS persistent inflammation, immunosuppression, and catabolism syndrome, VIF variance inflation factor, CI confidence interval, HbA1c glycated hemoglobin.